MYC and neoplasm: The tumour growth advantage was also supported by the upregulation of pAKT1, pMTOR, pRPS6, pEIF4EBP1, MKI67, MYC and HK2 and the downregulation of hsa‐miR‐429 (Figure 6C and Figure S9).